Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.74 |
| ▸ | FAP | Q12884 | 3/20 | 0.74 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.74 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.74 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.74 |
| ▸ | PREP | P48147 | 2/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12658453 | 0.92 | OPRM1 (0.66) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL12658497 | 0.92 | DPP4 (0.74) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL18780178 | 0.88 | FAP (0.58) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL12658504 | 0.88 | FAP (0.58) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL15386494 | 0.88 | FAP (0.58) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL29351630 | 0.87 | OPRM1 (0.58) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL21746949 | 0.86 | DPP4 (1.00) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL13263478 | 0.85 | DPP4 (0.70) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL12658519 | 0.85 | DPP4 (0.70) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL18780182 | 0.85 | DPP4 (0.70) | DPP4FAPDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303435-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | BACH BIOSCIENCES, LLC | 2013-11-14 | — | — | US | disclosed |
| EP-2319523-A1 | Serine protease inhibitors | Trustees Of Tufts College (US) | 2011-05-11 | — | — | EP | disclosed |
| US-20100168032-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | TRUSTEES OF TUFTS COLLEGE (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303435-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | FAP, PREP, CTSC | DPP4 8/4885FAP 1/4885DPP8 21/4885 |
| US-20100168032-A1 | Smart Pro-Drugs of Serine Protease Inhibitors | FAP, PREP, CTSC | DPP4 8/4885FAP 1/4885DPP8 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.